<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01711177</url>
  </required_header>
  <id_info>
    <org_study_id>OPM3117-Dubois/Pham</org_study_id>
    <nct_id>NCT01711177</nct_id>
  </id_info>
  <brief_title>Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma</brief_title>
  <official_title>Effect of Travoprost 0.004% on Retinal Oximetry in Primary Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Université de Montréal</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is the second leading cause of blindness among seniors in Canada. It is often
      associated with an elevated intraocular pressure (IOP), but its exact mechanism is still
      largely unknown. Some studies have shown a link between glaucoma and changes in the amount of
      oxygen in the veins of the eye. The study aims to compare the amount of oxygen in ocular
      veins among three different groups using a spectrophotometer. This instrument is linked to a
      camera and can measure the quantity of oxygen in the veins using different characteristics of
      the blood inside.

      The groups of the study are: patients without glaucoma, patients suspected of glaucoma and
      patients newly diagnosed with glaucoma. The drug the investigators are using, Travoprost
      0.004%, will only be administered to the groups suspected or diagnosed with glaucoma.
      Travoprost 0.004% is already approved for use in Quebec and is part of standard care. Ten
      patients will be recruited into each group for a total of 30 patients in this study. All
      patients for the suspected or diagnosed groups will be recruited from the Jewish General
      Hospital. Subsequently all testing will be done at the École d'optométrie, Université de
      Montréal
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood Oxygenation</measure>
    <time_frame>1 hour</time_frame>
    <description>For each subject, all the measurements will be done during an 1 hour appointment.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Primary Open Angle Glaucoma</condition>
  <arm_group>
    <arm_group_label>Normal control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Normal patient placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glaucoma suspect</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Newly diagnosed glaucoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treated with Travoprost (0.04%)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Normal control</arm_group_label>
    <arm_group_label>Glaucoma suspect</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>travoprost</intervention_name>
    <description>Travatan Z is administered to newly diagnosed glaucoma patient</description>
    <arm_group_label>Newly diagnosed glaucoma</arm_group_label>
    <other_name>travatan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  good systemic health

          -  irido-corneal angle open

          -  intraocular pressure more than 18 mmHg

        Exclusion Criteria:

          -  having cardiovascular problem

          -  Hypertension or diabetes

          -  under systemic medication for high blood pressure

          -  had an ocular surgery in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3t1P1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2012</study_first_submitted>
  <study_first_submitted_qc>October 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2012</study_first_posted>
  <results_first_submitted>June 16, 2016</results_first_submitted>
  <results_first_submitted_qc>June 16, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 28, 2016</results_first_posted>
  <last_update_submitted>June 16, 2016</last_update_submitted>
  <last_update_submitted_qc>June 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Montréal</investigator_affiliation>
    <investigator_full_name>Pierre Forcier</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>primary open angle glaucoma</keyword>
  <keyword>retinal oximetry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Normal Control</title>
          <description>Normal patient placebo
placebo: Placebo</description>
        </group>
        <group group_id="P2">
          <title>Glaucoma Suspect</title>
          <description>Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
placebo: Placebo</description>
        </group>
        <group group_id="P3">
          <title>Newly Diagnosed Glaucoma</title>
          <description>Treated with Travoprost (0.04%)
travoprost: Travatan Z is administered to newly diagnosed glaucoma patient</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Normal Control</title>
          <description>Normal patient placebo
placebo: Placebo</description>
        </group>
        <group group_id="B2">
          <title>Glaucoma Suspect</title>
          <description>Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
placebo: Placebo</description>
        </group>
        <group group_id="B3">
          <title>Newly Diagnosed Glaucoma</title>
          <description>Treated with Travoprost (0.04%)
travoprost: Travatan Z is administered to newly diagnosed glaucoma patient</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="5"/>
                    <measurement group_id="B2" value="53" spread="8"/>
                    <measurement group_id="B3" value="60" spread="9"/>
                    <measurement group_id="B4" value="55" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Blood Oxygenation</title>
        <description>For each subject, all the measurements will be done during an 1 hour appointment.</description>
        <time_frame>1 hour</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Normal Control</title>
            <description>Normal patient placebo
placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Glaucoma Suspect</title>
            <description>Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
placebo: Placebo</description>
          </group>
          <group group_id="O3">
            <title>Newly Diagnosed Glaucoma</title>
            <description>Treated with Travoprost (0.04%)
travoprost: Travatan Z is administered to newly diagnosed glaucoma patient</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Oxygenation</title>
          <description>For each subject, all the measurements will be done during an 1 hour appointment.</description>
          <units>percentage of oxygenation</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60" lower_limit="55" upper_limit="63"/>
                    <measurement group_id="O2" value="60" lower_limit="55" upper_limit="63"/>
                    <measurement group_id="O3" value="60" lower_limit="55" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Normal Control</title>
          <description>Normal patient placebo
placebo: Placebo</description>
        </group>
        <group group_id="E2">
          <title>Glaucoma Suspect</title>
          <description>Patients with elevated Intraocular pressure higher than 18 mmHg (placebo)
placebo: Placebo</description>
        </group>
        <group group_id="E3">
          <title>Newly Diagnosed Glaucoma</title>
          <description>Treated with Travoprost (0.04%)
travoprost: Travatan Z is administered to newly diagnosed glaucoma patient</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pierre Forcier</name_or_title>
      <organization>Université de Montreal</organization>
      <phone>514-343-7468</phone>
      <email>pierre.forcier@umontreal.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

